In June 2010, Neurocrine Biosciences entered into an exclusive worldwide collaboration with AbbVie (formerly Abbott) to develop and commercialize elagolix for women’s and men’s health. Under the terms of the agreement with AbbVie, AbbVie is responsible for future development and commercialization. In 2018, AbbVie received approval for ORILISSA® (elagolix) to treat pain associated with endometriosis. AbbVie is responsible for all development, marketing and commercialization costs and Neurocrine Biosciences is entitled to a royalty on worldwide sales of ORILISSA and elagolix.
Mitsubishi Tanabe Pharma
In March 2015, Neurocrine Biosciences entered into an exclusive collaboration and licensing agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of valbenazine for movement disorders in Japan and other select Asian markets.
Mitsubishi Tanabe will be responsible for all development, marketing and commercialization costs in their territories and Neurocrine Biosciences will be entitled to a percentage of sales by Mitsubishi Tanabe. Neurocrine Biosciences retains full commercial rights to valbenazine in North America, Europe and other countries outside of Asia.
On February 9, 2017, Neurocrine Biosciences entered into an exclusive licensing agreement with BIAL for the development and commercialization of opicapone in the United States and Canada. Opicapone is a once-daily, peripherally-acting, selective COMT inhibitor that was approved in June 2016 by the European Commission as an adjunct therapy for adult patients with Parkinson’s disease. Neurocrine Biosciences is responsible for the management and cost of all opicapone development and commercialization activities in the United States and Canada. In July 2019, Neurocrine Biosciences announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for opicapone as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes. The FDA has set a standard 12-month review process with a Prescription Drug User Fee Act (PDUFA) target action date of April 26, 2020.
On October 9, 2018, Neurocrine Biosciences entered into a research collaboration with Jnana Therapeutics aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders.
On January 29, 2019, Neurocrine Biosciences entered into a strategic collaboration with Voyager Therapeutics focused on the development and commercialization of Voyager’s gene therapy programs, NBIb-1817 for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia, as well as rights to two programs to be determined.